4.5 Article

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 71, Issue 6, Pages 1000-1010

Publisher

WILEY
DOI: 10.1002/art.40827

Keywords

-

Categories

Funding

  1. European Commission's Seventh Framework Programme (Information Communication Technologies Programme) [600932]

Ask authors/readers for more resources

ObjectiveTo assess the composition of gut microbiota in Italian and Dutch patients with juvenile idiopathic arthritis (JIA) at baseline, with inactive disease, and with persistent activity compared to healthy controls. MethodsIn a multicenter, prospective, observational cohort study, fecal samples were collected at baseline from 78 Italian and 21 Dutch treatment-naive JIA patients with <6 months of disease duration and compared to 107 geographically matched samples from healthy children. Forty-four follow-up samples from patients with inactive disease and 25 follow-up samples from patients with persistent activity were analyzed. Gut microbiota composition was determined by 16S ribosomal RNA-based metagenomics. Alpha- and -diversity were computed, and log ratios of relative abundance were compared between patients and healthy controls using random forest models and logistic regression. ResultsBaseline samples from Italian patients showed reduced richness compared to healthy controls (P < 0.001). Random forest models distinguished between Italian patient baseline samples and healthy controls and suggested differences between Dutch patient samples and healthy controls (areas under the curve >0.99 and 0.71, respectively). The operational taxonomic units (OTUs) of Erysipelotrichaceae (increased in patients), Allobaculum (decreased in patients), and Faecalibacterium prausnitzii (increased in patients) showed different relative abundance in Italian patient baseline samples compared to controls after controlling for multiple comparisons. Some OTUs differed between Dutch patient samples and healthy controls, but no evidence remained after controlling for multiple comparisons. No differences were found in paired analysis between Italian patient baseline and inactive disease samples. ConclusionOur findings show evidence for dysbiosis in JIA patients. Only patient/control status, age, and geographic origin appear to be drivers of the microbiota profiles, regardless of disease activity stage, inflammation, and markers of autoimmunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis

Michelle M. A. Kip, Sytze de Roock, Gillian Currie, Deborah A. Marshall, Luiza R. Grazziotin, Marinka Twilt, Rae S. M. Yeung, Susanne M. Benseler, Sebastiaan J. Vastert, Nico Wulffraat, Joost F. Swart, Maarten J. IJzerman

Summary: This study investigates medication prescription patterns in children with JIA, revealing the complexity of pharmacological treatment in terms of the variety of mono- and combination therapies prescribed, significant variation in medication prescriptions between subtypes, most patients receiving multiple treatment lines, and a large number of unique treatment sequences.

RHEUMATOLOGY (2023)

Article Rheumatology

Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry

Natalie J. Shiff, Peter Shrader, Colleen K. Correll, Anne Dennos, Thomas Phillips, Timothy Beukelman

Summary: This study describes the trajectories of disease activity scores in patients with Juvenile Arthritis (JIA) over a two-year period. Five distinct trajectories were identified, and their associated baseline characteristics were analyzed.

RHEUMATOLOGY (2023)

Article Rheumatology

Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation

Ann-Sophie De Craemer, Torsten Witte, Triana Lobaton Ortega, Anne Hoorens, Martine De Vos, Claude Cuvelier, Sebastiaan J. Vastert, Xenofon Baraliakos, Filip Van den Bosch, Dirk Elewaut

Summary: Serum anti-CD74 IgA is a potentially useful diagnostic biomarker for axSpA, but is not associated with gut inflammation or other disease-specific features.

RHEUMATOLOGY (2023)

Article Immunology

Human TH17 cells engage gasdermin E pores to release IL-1a on NLRP3 inflammasome activation

Ying-Yin Chao, Alisa Puhach, David Frieser, Mahima Arunkumar, Laurens Lehner, Thomas Seeholzer, Albert Garcia-Lopez, Marlot van der Wal, Silvia Fibi-Smetana, Axel Dietschmann, Thomas Sommermann, Tamara Cikovic, Leila Taher, Mark S. Gresnigt, Sebastiaan J. Vastert, Femke van Wijk, Gianni Panagiotou, Daniel Krappmann, Olaf Gross, Christina E. Zielinski

Summary: In this study, it was discovered that human T cells express GSDME, which is associated with durable viability and the release of IL-1 alpha. This property is only present in a subset of human helper type 17 T cells with specificity for Candida albicans, regulated by the T cell-intrinsic NLRP3 inflammasome. The release of IL-1 alpha is mediated by a proteolytic cascade involving caspase-8, caspase-3, and GSDME cleavage, as well as T cell receptor stimulation and calcium-licensed calpain maturation of pro-IL-1 alpha form. This finding expands our understanding of the functional diversity and mechanism of T cells and has implications for antifungal immunity.

NATURE IMMUNOLOGY (2023)

Article Rheumatology

Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition

Janneke G. C. Peeters, Arjan Boltjes, Rianne C. Scholman, Stephin J. Vervoort, Paul J. Coffer, Michal Mokry, Sebastiaan J. Vastert, Femke van Wijk, Jorg van Loosdregt

Summary: This study investigates the epigenetic changes in monocytes derived from inflamed joints of JIA patients and reveals the role of the local inflammatory environment in regulating these changes. The activation phenotype of synovial-derived monocytes is found to be regulated on the epigenetic level, with increased expression and epigenetic alterations in IFN signaling-associated genes. Treatment with the JAK inhibitor ruxolitinib transforms the activated enhancer landscape and reduces disease-associated gene expression, thus inhibiting the inflammatory phenotype.

RHEUMATOLOGY (2023)

Article Rheumatology

Patients' and parents' satisfaction to improve patient care in JIA: factors determining acceptable symptom state measured with JAMAR

Emanuela Del Giudice, Sytze de Roock, Sebastiaan J. Vastert, Nico M. Wulffraat, Joost F. Swart, Evert H. P. van Dijkhuizen

Summary: This study aimed to identify factors associated with satisfaction with JIA care reported by patients and parents. The study found that satisfaction was related to factors such as duration of morning stiffness, age at disease onset, disease duration, and patient well-being. For parents, satisfaction was related to disease activity, school problems, and quality of life. These findings highlight the importance of incorporating patient and parent perspectives into shared decision-making to improve the quality of medical care.

RHEUMATOLOGY (2023)

Article Biology

Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis

Gerdien Mijnheer, Nila Hendrika Servaas, Jing Yao Leong, Arjan Boltjes, Eric Spierings, Phyllis Chen, Liyun Lai, Alessandra Petrelli, Sebastiaan Vastert, Rob J. de Boer, Salvatore Albani, Aridaman Pandit, Femke van Wijk, Di Chen

Summary: Autoimmune inflammation is characterized by tissue infiltration and expansion of antigen-specific T cells. In this study, the authors used CyTOF analysis and TCR sequencing to investigate the immune cell composition and expansion of specific T cell clones in juvenile idiopathic arthritis (JIA). They found that the infiltrates in different affected joints of the same patient were similar, and dominant T cell clones, including Tregs, persisted over time. These findings suggest the presence of autoantigen-driven expansion of T cell clones in localized autoimmune disease.

ELIFE (2023)

Article Immunology

Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study

Milou Ohm, Joeri W. van Straalen, Marieke Zijlstra, Gerrie de Joode-Smink, Anne Jasmijn Sellies, Joost F. Swart, Sebastiaan J. Vastert, Joris M. van Montfrans, Marije Bartels, Annet van Royen-Kerkhof, Joanne G. Wildenbeest, Caroline A. Lindemans, Victorien M. Wolters, Roos A. W. Wennink, Joke H. de Boer, Mirjam J. Knol, Marloes W. Heijstek, Elisabeth A. M. Sanders, Frans M. Verduyn-Lunel, Guy A. M. Berbers, Nico M. Wulffraat, Marc H. A. Jansen

Summary: This study investigated the immunogenicity of the meningococcal serogroup ACWY conjugate vaccine in minors with juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD). The results showed that the concentrations of antibodies for serotypes A and W were lower in patients compared to healthy controls, and patients using anti-TNF therapy had lower immune response. Therefore, an extra booster vaccination should be considered for these patients.

VACCINE (2023)

Article Cell Biology

Pyruvate metabolism controls chromatin remodeling during CD4+T cell activation

Enric Mocholi, Laura Russo, Keshav Gopal, Andrew G. Ramstead, Sophia M. Hochrein, Harmjan R. Vos, Geert Geeven, Adeolu O. Adegoke, Anna Hoekstra, Robert M. van Es, Jose Ramos Pittol, Sebastian Vastert, Jared Rutter, Timothy Radstake, Jorg van Loosdregt, Celia Berkers, Michal Mokry, Colin C. Anderson, Ryan M. O'Connell, Martin Vaeth, John Ussher, Boudewijn M. T. Burgering, Paul J. Coffer

Summary: Upon antigen-specific TCR engagement, the generation of extramitochondrial pyruvate is crucial for acetyl-CoA production and subsequent histone acetylation remodeling. PDH-deficient T cells show that PDH-dependent acetyl-CoA production is a rate-limiting step during T cell activation. This study highlights the integration of metabolic and histone-modifying enzymes in CD4+ T cell activation, suggesting a potential therapeutic approach for regulating antigen-driven T cell activation.

CELL REPORTS (2023)

Article Medicine, General & Internal

Evaluation of Autoantibody Binding to Cardiac Tissue in Multisystem Inflammatory Syndrome in Children and COVID-19 Vaccination-Induced Myocarditis

Harsita Patel, Amalia Sintou, Rasheda A. Chowdhury, Stephen Rothery, Alma Octavia Iacob, Sanjay Prasad, Peter P. Rainer, Federico Martinon-Torres, Vanessa Sancho-Shimizu, Chisato Shimizu, Kirsten Dummer, Adriana H. Tremoulet, Jane C. Burns, Susanne Sattler, Michael Levin

Summary: This study investigated the presence of anticardiac autoantibodies in MIS-C or COVID-19 vaccine-induced myocarditis and found no evidence of antibody binding to cardiac tissue in these conditions. This suggests that the cardiac pathology in MIS-C and vaccine-induced myocarditis is unlikely to be driven by direct anticardiac antibody-mediated mechanisms.

JAMA NETWORK OPEN (2023)

Article Rheumatology

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

Bita Shakoory, Ashley Geerlinks, Marta Wilejto, Kate Kernan, Melissa Hines, Micol Romano, David Piskin, Angelo Ravelli, Rashmi Sinha, Daniel Aletaha, Carl Allen, Hamid Bassiri, Edward M. Behrens, Joseph Carcillo, Linda Carl, Winn Chatham, Jeffrey Cohen, Randy Q. Cron, Erik Drewniak, Alexei A. Grom, Lauren A. Henderson, Annacarin Horne, Michael B. Jordan, Kim E. Nichols, Grant Schulert, Sebastiaan Vastert, Erkan Demirkaya, Raphaela Goldbach-Mansky, Fabrizio de Benedetti, Rebecca A. Marsh, Scott W. Canna, HLH MAS Task Force

Summary: Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening hyperinflammatory syndromes that can develop in many inflammatory conditions. Early identification and management are crucial to prevent organ failure and mortality. This effort aimed to provide evidence-based guidance to assist clinicians in optimizing decision-making in the early stages of HLH/MAS.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)

Bita Shakoory, Ashley Geerlinks, Marta Wilejto, Kate Kernan, Melissa Hines, Micol Romano, David Piskin, Angelo Ravelli, Rashmi Sinha, Daniel Aletaha, Carl Allen, Hamid Bassiri, Edward M. Behrens, Joseph Carcillo, Linda Carl, Winn Chatham, Jeffrey I. Cohen, Randy Q. Cron, Erik Drewniak, Alexei A. Grom, Lauren A. Henderson, Annacarin Horne, Michael B. Jordan, Kim E. Nichols, Grant Schulert, Sebastiaan Vastert, Erkan Demirkaya, Raphaela Goldbach-Mansky, Fabrizio de Benedetti, Rebecca A. Marsh, Scott W. Canna

Summary: This study aims to provide evidence-based and consensus-based guidance for clinicians in the early diagnosis, treatment, and monitoring of HLH/MAS. Through research, questionnaires, and expert opinions, 6 overarching statements and 24 specific points to consider were developed, covering various aspects including early recognition, diagnosis, treatment, and monitoring. The involvement of multidisciplinary expertise is crucial for timely intervention and management.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial

Marco Gattorno, Laura Obici, Inmaculada Calvo Penades, Tilmann Kallinich, Susanne Benseler, Elise Dekker, Jeremy Levy, Fabrizio De Benedetti, Helen Lachmann

Summary: This study assessed the efficacy, safety, and tolerability of canakinumab in TRAPS patients during a 72-week long-term, open-label extension. The results showed that long-term canakinumab treatment effectively controlled disease activity and reduced flare incidence in TRAPS patients. No new safety concerns were identified.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants

Remco G. A. Erkens, Jorg J. A. Calis, Anouk Verwoerd, Sytze De Roock, Nienke M. Ter Haar, Gerda Den Engelsman, Lars T. van der Veken, Robert F. Ernst, Hanneke W. M. Van Deutekom, Alex Pickering, Rianne C. Scholman, Marc H. A. Jansen, Joost F. Swart, Rashmi Sinha, Johannes Roth, Grant S. Schulert, Alexei A. Grom, Jorg Van Loosdregt, Sebastiaan J. Vastert

Summary: Using anakinra as first-line treatment in new-onset sJIA patients resulted in high rates of clinical inactive disease, regardless of HLA-DRB1 or IL1RN variants. Early initiation of biologic therapy may be more appropriate for patients with different genetic susceptibility backgrounds.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Efficacy and safety of emapalumab in macrophage activation syndrome

Fabrizio De Benedetti, Alexei A. Grom, Paul A. Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Grant S. Schulert, Pierre Quartier, Jordi Anton, Christian Laveille, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Philippe Jacqmin, Cristina de Min

Summary: The objective of this study was to confirm the adequacy of an emapalumab dosing regimen in relation to interferon-γ (IFN-γ) activity and assess its efficacy and safety in treating MAS secondary to sJIA or AOSD. The results showed that emapalumab was efficacious in inducing remission of MAS and viral infections were observed.

ANNALS OF THE RHEUMATIC DISEASES (2023)

No Data Available